Basic Drug Info
Drug Name:Brimonidine
Other Info:

Pharmacokinetics: After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.

In humans, systemic metabolism of brimonidine is extensive.

It is metabolized primarily by the liver.

Urinary excretion is the major route of elimination of the drug and its metabolites.

Approximately 87% of an orally-administered radioactive dose was eliminated within 120 hours, with 74% found in the urine.

Clinical Trials:

Indications and Usage

Brimonidine tartrate ophthalmic solution is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The IOP lowering efficacy of Brimonidine tartrate ophthalmic solution diminishes over time in some patients.

This loss of effect appears with a variable time of onset in each patient and should be closely monitored.
Ocular hypotony -- Abnormally low intraocular pressure often related to chronic inflammation (uveitis).

Open Angle Glaucoma -- Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.

Ocular Hypertension -- A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.


Brimonidine tartrate ophthalmic solution is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication.

It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.
Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.

This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor. It should not to be used for self-diagnosis or treatment.